Apnimed
APMD
17.90
-0.15
-0.80%
Apnimed
US · APMD
#3463 by market cap
Listed 2026
17.90
-0.15
-0.80%
Live - 5344 symbols - heartbeat 395s ago
· 2026-10-08 09:58
Pre-market
18.03
-0.06%
After-hours
18.04
0.00%
Overnight
17.47
-3.16%
- Market cap
- 744.98M
- P/E (TTM)i
- 4.59
- P/Bi
- -4.23
- EPSi
- -3.22
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on APMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -9.62, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Latest year +380.12% YoY
Margins
- Gross margin
- 82.60%
- Operating margin
- -139.91%
- Net margin
- -2.42%
Key ratios & quality
- Enterprise valuei
- 743.99M
- Altman Z-Scorei
- -9.62
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 8.01M | 38.47M |
| Gross profit | 4.64M | 31.77M |
| Selling & admin expenses | 21.50M | 23.49M |
| Research & development | 97.38M | 62.10M |
| Operating profit | -114.23M | -53.82M |
| Pretax profit | -108.55M | -932.00K |
| Tax | 51.00K | 0 |
| Net profit | -111.31M | -932.00K |
| Basic EPS | -4 | 0 |
| Diluted EPS | -3.87 | -0.03 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | 3.13M | 17.11M | 38.47M | 12.08M |
| Gross profit | 1.81M | 15.39M | 82.65M | 10.87M |
| Selling & admin expenses | 5.47M | 5.35M | 6.51M | 12.67M |
| Research & development | 23.46M | 15.97M | 8.10M | 9.90M |
| Operating profit | -27.11M | -5.94M | 68.04M | -11.70M |
| Pretax profit | -26.68M | -5.63M | 70.37M | 126.11M |
| Tax | 0 | 0 | 0 | 0 |
| Net profit | -28.65M | -69.47M | 70.37M | 125.94M |
| Basic EPS | -1 | -2 | 2 | 3 |
| Diluted EPS | -1.00 | -2.42 | 2.12 | 3.16 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 73.25M | 45.06M |
| Cash & ST investments | 68.35M | 41.89M |
| Inventory | -- | -- |
| Total assets | 109.22M | 72.87M |
| Total current liabilities | 42.36M | 110.88M |
| Short-term debt | 222.00K | 250.00K |
| Long-term debt | -- | 40.65M |
| Total liabilities | 357,838,000.00 | 445,656,000.00 |
| Total equity | -248.62M | -372.78M |
| Retained earnings | -269.15M | -397.34M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 332.00M | 184.77M |
| Cash & ST investments | -- | -- | 328.88M | 172.80M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 342.63M | 195.46M |
| Total current liabilities | -- | -- | 38.39M | 35.58M |
| Short-term debt | -- | -- | 257.00K | 265.00K |
| Long-term debt | -- | -- | 46.10M | 79.60M |
| Total liabilities | -- | -- | 85,044,000.00 | 371,637,000.00 |
| Total equity | -- | -- | 257.59M | -176.18M |
| Retained earnings | -- | -- | -186.97M | -203.69M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -110.21M | -77.83M |
| Depreciation & amortization | 23.00K | 27.00K |
| Free cash flow | -110.28M | -77.83M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 68.35M | 41.89M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -28.45M | -17.37M | -19.81M | -18.11M |
| Depreciation & amortization | 7.00K | 6.00K | 6.00K | 7.00K |
| Free cash flow | -28.45M | -17.37M | -19.81M | -18.45M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 39.90M | 38.82M | 46.89M | 172.80M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -101.91 | -1.02 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -1,425.79 | -139.91 |
| FCF / sales %i | -- | -- |
| Current ratioi | 1.73 | 0.41 |
| Quick ratioi | 1.64 | 0.39 |
| Debt / assetsi | 1.00 | 56.97 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | 38.08 | -- |
| ROA %i | -- | -- | 28.63 | 148.80 |
| ROIC %i | -- | -- | 31.82 | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | 34.41 | 30.90 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 8.65 | 5.19 |
| Quick ratioi | -- | -- | 8.59 | 4.88 |
| Debt / assetsi | -- | -- | 13.69 | 41.11 |
| LT debt / equityi | -- | -- | 18.11 | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of novel oral therapies that address the neurobiology100.00%
Quote time 2026-10-08 09:58:32 · For reference only, not investment advice and not tailored to your situation.